Bristol Myers Squibb Expands Direct-to-Patient Program with Eliquis and Sotyktu Discounts

What's Happening?

Bristol Myers Squibb has announced an expansion of its direct-to-patient offerings, providing significant discounts for Eliquis and Sotyktu to eligible U.S. patients. The initiative aims to reduce out-of-pocket costs for patients by offering Eliquis at a more than 40% discount and Sotyktu at over 80% discount from the current list price. The BMS Patient Connect platform will facilitate the purchase and delivery of these medications directly to patients across the United States and Puerto Rico. This move is part of Bristol Myers Squibb's strategy to make its innovative medicines more accessible and affordable, particularly for patients with serious conditions.

Why It's Important?

The expansion of Bristol Myers Squibb's direct-to-patient program is significant as it addresses the high cost of prescription medications, a major concern for many patients in the U.S. By offering substantial discounts, the company is helping to alleviate financial barriers that prevent patients from accessing necessary treatments. This initiative could potentially improve patient adherence to prescribed therapies, leading to better health outcomes. Additionally, it reflects a growing trend in the pharmaceutical industry towards direct-to-consumer models, which can enhance transparency and patient engagement.

What's Next?

Bristol Myers Squibb plans to continue expanding its direct-to-patient offerings, potentially adding more medications to the BMS Patient Connect platform. The company will also provide patient support resources to ensure patients have the necessary information and assistance to manage their conditions effectively. As the program evolves, it may set a precedent for other pharmaceutical companies to adopt similar models, further transforming the landscape of drug distribution and patient access.